Pharmasset Investor Challenges $11B Gilead Deal
A Pharmasset Inc. shareholder launched a proposed class action Tuesday challenging Gilead Sciences Inc.'s $11 billion acquisition of the drugmaker, saying the offer shortchanges shareholders despite a hefty 89 percent premium....To view the full article, register now.
Already a subscriber? Click here to view full article